1112-1113 / 1578
Factors influencing choice of ablative modality
Need for tissue (mutations, PDL1 expression, liquid biopsies)
Location (brain, bone/vertebra, liver, liver hilus, central lung)
Size of lesion (>3 cm cutoff)
Previous treatments (high-dose radiation, surgery)
Co-morbidities, patient preferences, institutional experience
Timing (phased treatments, initial systemic therapy)
Enhancement of immune function (SABR)
Senan S, ESMO 2017